Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

8.77USD
18 Aug 2017
Change (% chg)

$-0.01 (-0.11%)
Prev Close
$8.78
Open
$8.75
Day's High
$8.86
Day's Low
$8.65
Volume
603,206
Avg. Vol
804,275
52-wk High
$13.38
52-wk Low
$3.11

Latest Key Developments (Source: Significant Developments)

Array Biopharma reports Q4 loss per share $0.17
Wednesday, 9 Aug 2017 06:00am EDT 

Aug 9 (Reuters) - Array Biopharma Inc :Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017.Q4 loss per share $0.17.Q4 revenue $33.8 million versus I/B/E/S view $28.6 million.Q4 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Array Biopharma Inc - ‍Entered into a license, development and commercialization partnership with Ono Pharmaceutical for binimetinib and encorafenib​.Array Biopharma Inc - ‍Ono received rights to develop and commercialize binimetinib and encorafenib in Japan and South Korea​.Array Biopharma - ‍Received upfront payment of $31.2 million, retains exclusive commercialization rights for binimetinib, encorafenib in U.S., Canada, Israel​.Array Biopharma Inc - ‍Is entitled to receive up to an additional $156 million (¥17.3 billion) if certain development and commercial milestones are achieved​.Array Biopharma Inc - ‍Will be eligible for robust, tiered, double-digit royalties based on product sales in Japan and South Korea​.  Full Article

Amgen and Array BioPharma announce preclinical license and collaboration agreement
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - Array BioPharma Inc :Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation.Array BioPharma - under terms of agreement, Amgen and Array will collaborate on preclinical development with Array leading medicinal chemistry work.Array BioPharma Inc - ‍Amgen is responsible for clinical development and commercialization​.Array BioPharma - in exchange for exclusive rights to Array's preclinical program, Amgen will make upfront and milestone payments.Array BioPharma - Amgen will also pay royalties on sales of resulting therapies.  Full Article

Array Biopharma submits new drug applications to FDA
Wednesday, 5 Jul 2017 08:00am EDT 

July 5 (Reuters) - Array Biopharma Inc ::Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma.Array Biopharma Inc - ‍further results from columbus part 2 will be presented at a medical meeting during second half of 2017​.Array Biopharma- ‍submission of two NDAs to FDA to support use of combination of binimetinib 45 mg twice daily, encorafenib 450 mg once daily.  Full Article

Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor
Wednesday, 31 May 2017 04:04am EDT 

May 31 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and.* Says Binimetinib and encorafenib are currently in two global Phase III trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal.* Under the terms of the agreement, ONO will pay to Array an upfront payment of 3.5 billion yen and milestones up to 17.3 billion yen and other expenses .  Full Article

Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds
Wednesday, 31 May 2017 03:00am EDT 

May 31 (Reuters) - Array Biopharma Inc :Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib.Array Biopharma says Array to receive $31.6 million up-front payment and up to $156.0 million in additional development and commercial milestones.Ono will receive rights to develop and commercialize Binimetinib and Encorafenib in Japan and South Korea.  Full Article

Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
Tuesday, 30 May 2017 06:59am EDT 

May 30 (Reuters) - Array BioPharma Inc :Array bioPharma and Bristol-Myers Squibb announce strategic collaboration.Bristol-Myers Squibb Co says under terms of agreement, Array and Bristol-Myers Squibb will jointly support study with Array acting as sponsor.Bristol-Myers Squibb Co - Collaboration to investigate safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib.Bristol-Myers Squibb Co says phase 1/2 study is expected to establish recommended dose regimens for further study.Bristol-Myers Squibb Co says results from phase 1/2 study, which is anticipated to begin in second half of 2017.Bristol-Myers Squibb Co - Collaboration to investigate binimetinib with co's opdivo (nivolumab) and opdivo + yervoy (ipilimumab) regimen.Bristol-Myers Squibb Co - Collaboration for potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.  Full Article

Array BioPharma Q3 loss per share $0.21
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Array Biopharma Inc :Array biopharma reports financial results for the third quarter of fiscal 2017.Q3 loss per share $0.21.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.Q3 revenue $33.3 million versus i/b/e/s view $37 million.Array biopharma inc - is on track to file an nda for columbus in june or july 2017.Array biopharma inc - revenue for q3 of fiscal 2017 was $33.3 million, compared to $44.5 million for prior sequential quarter.Array biopharma inc - cash, cash equivalents and marketable securities as of march 31, 2017 were $207 million.  Full Article

Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Array Biopharma Inc :Array Biopharma announces positive top-line results from part 2 of the phase 3 Columbus study of binimetinib and encorafenib for braf-mutant melanoma.Array Biopharma Inc - new drug application filing on track for June or July 2017.Array - median PFS for patients on combination of binimetinib (45mg) plus encorafenib (300mg) 12.9 months versus 9.2 months for patients on encorafenib (300mg).Array Biopharma Inc- COMBO300 generally well-tolerated, reported dose intensity, adverse events were consistent with COMBO450 results in Columbus part 1.  Full Article

Array enters into loan, security agreement
Friday, 23 Dec 2016 04:24pm EST 

Array Biopharma Inc : Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for term loan in original principal amount of $15 million . Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million . Array Biopharma Inc - loan agreement also provides for revolving line of credit of up to $5 million - SEC filing .Array Biopharma -co requested issuance of letter of credit of $2.8 million to secure obligations under lease agreement for Boulder, Colorado facilities.  Full Article

Array Biopharma prices public offering at $6.25 per share
Tuesday, 27 Sep 2016 09:25pm EDT 

Array Biopharma Inc : Array Biopharma announces pricing of public offering of common stock .Says public offering of 18.4 million common shares priced at $6.25 per share.  Full Article

BRIEF-Array Biopharma appoints Curtis Oltmans as general counsel

* Array Biopharma appoints Curtis Oltmans as general counsel Source text for Eikon: Further company coverage: